Device clinical trial

NanoJect

NanoJect – device for vaccine intradermal injection

Status: Study completed
Number of volunteers: 66
Lenght of the study: 2
months

​​​​​​​Intradermal Rabies Immunization using NanoJect™: A comparative study

​​​​​​​This clinical trial aims to evaluate a new injection device (NanoJect™) designed to administer vaccines or drugs by intradermal route. To do this, three different techniques for administering the “Vaccin rabique Pasteur®, Verorab” will be performed and compared at the level of the immunogenicity and the safety: intramuscular injection with a syringe, intradermal injection with a syringe and intradermal injection with the NanoJect™.

66 healthy volunteers, men and women, aged 18-50 years old, who never received rabies vaccine, will be enrolled at the Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, for 2 months. A total of 5 visits are scheduled including a full medical check-up, 3 immunization visits and one follow-up visit with blood samples.

For further information on this study, please contact us by phone 021 314 11 60/63.

Contact

Division of Immunology and Allergy
Monday to Friday: 8 am - 6 pm
Vaccine and Immunotherapy Center
1011 Lausanne, Suisse
Tél. +41 21 314 1160
Tél. +41 21 314 1163
Fax +41 21 314 1161
 Dernière mise à jour le 28/06/2019 à 08:09